Ovarian Seromucinous Carcinoma — Clinical Trials

MONDO:00040328 activeLast updated: Mar 20, 2026, 5:57 PM

Trial Landscape

Ovarian Seromucinous Carcinoma has a growing clinical research program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment9

Procedure7

Biological Therapy5

6 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Phase 3

Sponsor Types

NIH8Academic/Other2

Trial Locations

United States10 trials

Canada4 trials

South Korea4 trials

Japan3 trials

Puerto Rico3 trials

Singapore1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

10 Trials

Phase 3Active, Not Recruiting

NCT01167712

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2010Est. completion: Jul 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT02446600

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2016Est. completion: Nov 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT00565851

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2007Est. completion: Jan 2028Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT02101775

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2014Est. completion: Mar 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02502266

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04739800

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2021Est. completion: Nov 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02122185

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:University of Chicago

United StatesStarted: Feb 2015Est. completion: Feb 2027Updated: Jun 2025

Phase 1Active, Not Recruiting

NCT04092270

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2020Est. completion: Jun 2026Updated: Mar 2026

Stay informed about clinical trials for Ovarian Seromucinous Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 5:57 PM

Ovarian Seromucinous Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

10 Trials

Active Trials8

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Other2